Skapemed Original Nasal

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with colds, hay fever, or other upper respiratory allergies. Additionally, it provides temporary relief from sinus congestion and pressure.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 6 years and older, the recommended dosage is 2 to 3 sprays in each nostril. Administration should not occur more frequently than every 10 to 12 hours. It is important to note that the total number of doses should not exceed 2 doses within a 24-hour period. Adult supervision is required for children in this age group during administration.

Contraindications

Use of this product is contraindicated in the following situations:

• In children under 2 years of age.

• When the recommended dosage is exceeded.

• For use beyond 3 consecutive days. Prolonged or frequent use may lead to a recurrence or worsening of nasal congestion.

Warnings and Precautions

The use of this product is contraindicated in individuals with known allergies to any of its ingredients. Healthcare professionals should advise patients to consult a physician prior to use if they have a history of heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating due to an enlarged prostate gland.

During the administration of this product, it is imperative that patients adhere strictly to the recommended dosage guidelines. Exceeding the recommended dosage or using the product for more than three consecutive days is not advised, as such practices may lead to a recurrence or exacerbation of nasal congestion. Patients should be informed that temporary side effects, including burning, stinging, sneezing, or increased nasal discharge, may occur. Additionally, the use of this product by multiple individuals may pose a risk of infection transmission.

In the event of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Patients are advised to discontinue use and consult a healthcare provider if symptoms persist despite treatment. Regular monitoring of symptoms and adherence to these precautions is essential for safe and effective use of the product.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this product. Serious adverse reactions may occur in individuals who are allergic to any of the ingredients. It is advised that patients consult a healthcare professional prior to use if they have a history of heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating due to an enlarged prostate gland.

Common adverse reactions reported during use include temporary discomfort, which may manifest as burning, stinging, sneezing, or increased nasal discharge. These reactions are generally mild and transient. Patients are cautioned against exceeding the recommended dosage and should not use the product for more than three days, as frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

In the event that symptoms persist, patients are advised to discontinue use and consult a doctor. Additionally, it is important to note that the use of this product by more than one person may increase the risk of spreading infection.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Skapemed Original Nasal (naphazoline hcl 0.05%original nasal). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 2 years of age should not use this medication. For children aged 2 to under 6 years, it is advised to consult a healthcare professional before use.

In patients 6 years and older, the recommended dosage is 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. The total dosage should not exceed 2 doses within a 24-hour period. Adult supervision is required for this age group during administration.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of naphazoline HCL during pregnancy has not been established, as the prescribing information does not provide specific data regarding its use in pregnant patients. There are no known safety concerns, dosage modifications, or special precautions outlined for this medication in the context of pregnancy. Healthcare professionals should exercise caution when considering the use of naphazoline HCL in women of childbearing potential and weigh the potential benefits against any unknown risks to fetal outcomes. It is advisable to discuss the use of this medication with pregnant patients, considering the lack of available data.

Lactation

There is no specific information available regarding the use of this product in lactating mothers. Additionally, there is no data on the potential for excretion in breast milk or any related precautions for breastfeeding women. Healthcare professionals should consider this lack of information when advising lactating mothers.

Renal Impairment

Patients with renal impairment have no specific information regarding dosage adjustments or monitoring provided in the insert text. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the lack of data may necessitate careful consideration of potential risks and benefits. Regular monitoring of renal function is advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may arise from an overdose. Common symptoms may include, but are not limited to, severe drowsiness, confusion, respiratory distress, or any other unusual clinical manifestations.

Management of an overdose should be tailored to the individual patient and may involve supportive care, including monitoring vital signs and providing symptomatic treatment as necessary. In cases of significant overdose, consultation with a poison control center or a medical toxicologist is recommended to determine the most appropriate course of action.

It is crucial for healthcare professionals to educate patients and caregivers about the importance of adhering to prescribed dosages and to provide guidance on what to do in the event of a suspected overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Postmarketing experience has revealed reports of adverse reactions, including but not limited to burning, stinging, sneezing, and increased nasal discharge. Additionally, there have been instances of nasal congestion recurring or worsening with frequent or prolonged use.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed.

For children under 2 years of age, it is important to instruct caregivers to shake the bottle well before use. Prior to the first application, they should remove the protective cap, safely clip the tip, and prime the metered pump by firmly depressing it several times. When administering the spray, caregivers should hold the bottle with their thumb at the base and the nozzle between the first and second fingers. The nozzle should be inserted into the nostril without tilting the head, and the pump should be fully depressed with a firm, even stroke while the patient sniffs deeply. After use, the nozzle should be wiped clean.

Patients should be informed to stop using the product and consult a doctor if symptoms persist. It is crucial to emphasize that the recommended dosage should not be exceeded and that the product should not be used for more than 3 days. Patients should use the product only as directed, as frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Temporary discomfort, such as burning, stinging, sneezing, or increased nasal discharge, may occur during use. Additionally, healthcare providers should caution patients that using this container by more than one person may spread infection. For children aged 2 to under 6 years, specific guidance should be provided to ensure safe and effective use.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a temperature not exceeding 25°C to maintain its integrity and efficacy. Proper container requirements must be adhered to, ensuring that the product is kept in a suitable environment. Special handling needs should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

The route of administration for the medication is nasal. For adults and children aged 6 years and older, with adult supervision, the recommended dosage is 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important not to exceed 2 doses within a 24-hour period.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Skapemed Original Nasal, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)